NCT02056587View on ClinicalTrials.gov

Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

October 31, 2013

Conditions
Metastatic Renal Cell Carcinoma
Interventions
DRUG

Everolimus

All patients with metastatic renal cell carcinoma progressing on prior treatment with bevacizumab ± interferon enrolled into this study will receive everolimus in the dose of 10 mg daily until the disease progression or unacceptable toxicity.

Trial Locations (3)

115478

N.N. Blokhin Russian Cancer Research Center, Moscow

420029

Tatarstan Regional Cancer Center, Kazan'

Unknown

Altai Regional Cancer Center, Barnaul

All Listed Sponsors
lead

Kidney Cancer Research Bureau

OTHER

NCT02056587 - Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment | Biotech Hunter | Biotech Hunter